Cabaletta Bio (CABA) Share-based Compensation (2018 - 2025)

Cabaletta Bio's Share-based Compensation history runs 8 years deep, the most recent figure standing at $4.3 million for Q4 2025.

• On a quarterly basis, Share-based Compensation rose 237.75% year-over-year to $4.3 million in Q4 2025; TTM through Dec 2025 was $9.1 million, a 334.22% increase from a year earlier, with the FY2025 full-year figure at $20.9 million, up 91.0% from the prior year.
• Share-based Compensation slipped to $4.3 million in Q4 2025 per CABA's latest filing, from $38.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $47.4 million in Q2 2025 and bottomed at -$6.2 million in Q4 2023.
• The 5-year median for Share-based Compensation is $1.6 million (2021), against an average of $5.7 million.
• Across the five-year window, Share-based Compensation sank 495.69% in 2023 and soared 173535.06% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $1.6 million in 2021, then retreated by 1.44% to $1.6 million in 2022, then sank by 495.69% to -$6.2 million in 2023, then surged by 50.5% to -$3.1 million in 2024, then jumped by 237.75% to $4.3 million in 2025.
• Per Business Quant, the three latest CABA Share-based Compensation figures stand at $4.3 million (Q4 2025), $38.7 million (Q3 2025), and $47.4 million (Q2 2025).